3 February 2021
Patients with Parkinson’s disease (PD) and healthcare professionals caring for them have expressed concerns about the COVID-19 vaccine’s efficacy and safety in the specific context of PD and its symptomatic treatment. In a commentary just published in JPD, a set of experts addresses these concerns from an evidence-based perspective. Their conclusion is that COVID-19 vaccination with approved vaccines should be recommended to persons with PD, unless there is a specific contraindication.
26 January 2021
Amsterdam, NL – With medicinal cannabis now legalized in many parts of the world, there is growing interest in its use to alleviate symptoms of many illnesses including Parkinson’s disease (PD).
21 January 2021
Amsterdam, NL – The bacterial gut microbiome is strongly associated with Parkinson’s disease (PD), but no studies had previously investigated the role of fungi in the gut.
25 September 2020
Call for Submissions: To address the bias toward the publication of novel positive results, The Michael J. Fox Foundation for Parkinson’s Research and JPD invite researchers to “open their notebooks” and submit unpublished results from experiments that attempted to replicate previously published findings from other laboratories.
23 September 2020
Amsterdam, NL – Well over six million people globally have been diagnosed with Parkinson's disease, which has an enormous impact on the lives of patients and their families and incurring mounting costs for society.
22 September 2020
Is the world prepared a wave of neurological consequences that may be on its way as a result of COVID-19? This question is at the forefront of research underway at the Florey Institute of Neuroscience and Mental Health. A team of neuroscientists and clinicians are examining the potential link between COVID-19 and increased risk of Parkinson’s disease, and measures to get ahead of the curve.
3 August 2020
The Outlook Is Encouraging: Researchers Evaluate a Pipeline of Clinical Trials Targeting Parkinson's Disease
Amsterdam, NL – A review of currently registered clinical trials of agents targeting Parkinson's disease (PD) reveals that there is a broad pipeline of both symptomatic and potentially disease-modifying therapies currently being evaluated. Investigators report that the outlook for patients is encouraging, given the wide range of therapeutics being clinically tested. They emphasize the importance of engaging the Parkinson's community in the research. Their analysis and results are published in the >Journal of Parkinson's Disease.
22 July 2020
Amsterdam, NL – The Journal of Parkinson's Diseaseand its publisher IOS Press are proud to announce the two articles that have won the first Parkinson Prize, recognizing these outstanding contributions to the advancement to Parkinson's disease research. Recipients of the award are lead investigator Thomas Foltynie, MD, PhD (research article) and co-authors Heiko Braak, MD, and Kelly Del Tredici, MD, PhD (review article).
9 July 2020
Amsterdam, NL – Timely administration of anti-Parkinson drugs is a significant issue for hospitalized patients with Parkinson's disease (PD) with late or missed doses resulting in longer stays and worse outcomes.
7 July 2020
Amsterdam, NL – The Journal of Parkinson's Disease (JPD) and its publisher IOS Press are proud to announce that JPD's Journal Impact Factor has increased to 5.178 according to Clarivate's 2020 edition of the Web of Science Journal Citation Reports™ (JCR). This represents an impressive 40% increase from last year.